October 06, 2020
3 min watch
Save
VIDEO: Don’t leave PKI analysis behind in lung cancer immunotherapy
In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, highlighted findings from the PIONeeR trial, which was presented at ESMO Virtual Congress 2020.
“Pharmacokinetics is worthy of a bit more study in immunotherapies because ...some of [us] think that pharmacokinetics might not matter as much as they do with chemo-therapeutics,” Stevenson said. “But it may turn out that PKI analyses are important for immunotherapies as well.”
References:
- Barlesi F, et al. Abstract LBA53. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Stevenson reports receiving clinical trial research funding from Bristol-Meyers Squibb and Merck.
Read more about